Using advanced computational genomics, Johns Hopkins investigators discovered how prostate cancer develops resistance to ...

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

The U.S. FDA has expanded the indication for Johnson & Johnson's (JNJ) Akeega (niraparib and abiraterone) to include ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...

But a practice called integrative medicine, which combines conventional cancer therapies with complementary and holistic treatments, is increasingly being used to manage the disease. While ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

Medicare beneficiaries who were diagnosed with metastatic cancer experienced a mean of 40.1 to 62.9 healthcare contact days, including days in a hospital, emergency department, skilled nursing ...

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...